Phase 2 Vasculitis Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You weigh at least 40 kg (about 88 pounds)

• You are currently on a stable, prescribed treatment plan for your kidney condition, following local medical guidelines

• Your blood pressure at your screening visit is not too high (top number no more than 160, bottom number no more than 90)

• You have been diagnosed with one of these kidney conditions: IgA nephropathy (IgAN), IgA vasculitis with nephritis (IgAVN), primary membranous nephropathy (pMN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), or primary nephrotic syndrome

• If you are an adult (18+) with IgAN: Your diagnosis has been confirmed by a kidney biopsy, your kidneys are functioning at a certain minimum level, and you have a measurable amount of protein in your urine

• If you are a child (age 2–17) with IgAN or IgAVN: Your diagnosis has been confirmed by a kidney biopsy, you have been on a stable treatment for at least 8 weeks, your kidneys are functioning at a minimum level, and you have protein in your urine

• If you are an adult with pMN: Your diagnosis has been confirmed by a kidney biopsy, you have a specific antibody in your blood (anti-PLA2R) above a certain level, you have protein in your urine, and you are considered unlikely to get better on your own

• If you have nephrotic syndrome (MCD, FSGS, or childhood nephrotic syndrome): You are age 10 or older, your kidneys are functioning at a minimum level, you have protein in your urine, and you have a specific antibody called anti-nephrin in your blood

Who may not be able to join:

• Your kidney function has dropped by 50% or more in the 12 weeks before your screening visit
• You currently have an active viral or bacterial infection
• You have other health conditions or abnormal lab results that could interfere with safely taking part in the study (confirm with trial site)
• You have received a live vaccine in the 30 days before enrolling
• You have taken immune-suppressing medications in the 4 weeks before starting the study drug (with an exception for people on transplant anti-rejection medications)
• You have had an allergic reaction to atacicept (the study drug) or any of its ingredients in the past
• There are additional requirements specific to each disease group that may affect eligibility (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.